Brokers Offer Predictions for ACRV FY2024 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Acrivon Therapeutics in a research report issued on Monday, February 3rd. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($2.42) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.51) per share. Cantor Fitzgerald also issued estimates for Acrivon Therapeutics’ FY2025 earnings at ($2.55) EPS.

A number of other brokerages have also weighed in on ACRV. KeyCorp assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. Finally, BMO Capital Markets dropped their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.67.

Acrivon Therapeutics Trading Up 17.9 %

Shares of ACRV stock opened at $6.97 on Wednesday. The firm has a 50-day moving average price of $6.27 and a 200 day moving average price of $7.31. The company has a market capitalization of $217.02 million, a price-to-earnings ratio of -2.58 and a beta of 0.77. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $11.90.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Acrivon Therapeutics in the 4th quarter valued at approximately $40,000. Dimensional Fund Advisors LP acquired a new position in Acrivon Therapeutics in the second quarter worth $58,000. Barclays PLC grew its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after buying an additional 11,273 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after purchasing an additional 28,748 shares during the period. Finally, Exome Asset Management LLC bought a new stake in shares of Acrivon Therapeutics in the 3rd quarter worth approximately $817,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.